PLN 32.2
(1.58%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 97.29 Million PLN | -13.9% |
2022 | 113 Million PLN | -21.28% |
2021 | 143.54 Million PLN | 456.81% |
2020 | 25.77 Million PLN | 1.9% |
2019 | 25.29 Million PLN | 40.07% |
2018 | 18.06 Million PLN | 252.48% |
2017 | 5.12 Million PLN | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 77.65 Million PLN | -6.97% |
2024 Q1 | 83.46 Million PLN | -14.21% |
2023 Q3 | 72.54 Million PLN | -7.32% |
2023 Q2 | 78.27 Million PLN | -23.42% |
2023 FY | 97.29 Million PLN | -13.9% |
2023 Q4 | 97.29 Million PLN | 34.12% |
2023 Q1 | 102.2 Million PLN | -9.55% |
2022 Q1 | 134.02 Million PLN | -6.63% |
2022 Q4 | 113 Million PLN | -3.91% |
2022 FY | 113 Million PLN | -21.28% |
2022 Q3 | 117.6 Million PLN | -2.85% |
2022 Q2 | 121.04 Million PLN | -9.68% |
2021 Q2 | 157.12 Million PLN | 501.6% |
2021 FY | 143.54 Million PLN | 456.81% |
2021 Q1 | 26.11 Million PLN | 1.32% |
2021 Q4 | 143.54 Million PLN | -3.44% |
2021 Q3 | 148.64 Million PLN | -5.4% |
2020 FY | 25.77 Million PLN | 1.9% |
2020 Q2 | 29.36 Million PLN | 0.0% |
2020 Q4 | 25.77 Million PLN | 0.0% |
2019 FY | 25.29 Million PLN | 40.07% |
2019 Q4 | 25.29 Million PLN | 0.0% |
2018 FY | 18.06 Million PLN | 252.48% |
2017 FY | 5.12 Million PLN | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Bioceltix S.A. | 12.73 Million PLN | -663.971% |
BIOTON S.A. | 822.22 Million PLN | 88.167% |
Mabion S.A. | 208.25 Million PLN | 53.281% |
Molecure S.A. | 168.57 Million PLN | 42.285% |
NanoGroup S.A. | 8.63 Million PLN | -1027.186% |
Pharmena S.A. | 24.13 Million PLN | -303.174% |
Poltreg S.A. | 127.09 Million PLN | 23.45% |
Pure Biologics Spólka Akcyjna | 22.73 Million PLN | -327.892% |
Ryvu Therapeutics S.A. | 403.2 Million PLN | 75.87% |
Synthaverse S.A. | 265.9 Million PLN | 63.41% |
Urteste S.A. | 29.59 Million PLN | -228.718% |